Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Athale, Abha H ^a   Marcucci, Maura ^b   Iorio, Alfonso ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR;

ALLERGIC REACTION; APPLICATION SITE INFECTION; ARTICLE; BLEEDING; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; HEALTH CARE UTILIZATION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; JOINT FUNCTION; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THERAPY EFFECT;

EID: 85048501102     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010561     Document Type: Article

References (16)

1. Astermark J. Immune tolerance induction in patients with hemophilia A. Thrombosis Research 2011;127 Suppl 1:S6-S9.
2. Carcao M, St Louis J, Poon M-C, Grunebaum E, Lacroix S, Stain AM, et al.Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006;12(1):7-18.
3. Coppola A, Di Capua M, Di Minno MND, Di Palo M, Marrone E, Ieranò P, et al.Treatment of hemophilia: a review of current advances and ongoing issues. Journal of Blood Medicine 2010;1:183-95.
4. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
5. Di Michele DM. Immune tolerance induction in haemophilia: evidence and the way forward. Journal of Thrombosis and Haemostasis 2011;9(Suppl 1):216-25.
6. Di Minno MN, Di Minno G, Di Capua M, Cerbone AM, Coppola A. Cost of care of haemophilia with inhibitors. Haemophilia 2010;16(1):190-201.
7. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. British Journal of Haemophilia 2007;138(3):305-15.
8. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
9. Freedman J, Rand ML, Russell O, Davis C, Cheatley PL, Blanchette V, et al.Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion 2003;43(11):1508-13.
10. Freedman F, Garvey MB. Immunoadsorption of factor VIII inhibitors. Current Opinion in Hematology 2004;11(5):327-33.
11. Gringeri A, Mantovani LG, Scalone L, Mannucci PM, COCIS Study Group. Cost of care and quality of life for patients with haemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003;102(7):2358-63.
12. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
13. Mannucci P, Tuddenham E. The Hemophilias-- from royal genes to gene therapy. New England Journal of Medicine 2001;344(23):1773-9.
14. Scalone L, Mantovani LG, Mannicci PM, Gringeri A. Quality of life associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006;12(2):154-62.
15. Shemilt I, Mugford M, Byford S, Drummond M, Eisenstein E, Knapp M, et al.Chapter 15: Incorporating economics evidence. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
16. Tagliaferri A, Rivolta GF, Iorio A, Oliovecchio E, Mancuso ME, Mornini M, et al.Mortality and causes of death in Italian persons with haemophilia, 1990 - 2007. Haemophilia 2010;16(3):437-46.